The state of Minnesota currently has 329 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Minneapolis, Rochester, Saint Paul and Duluth.
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
NCT04197687
Recruiting
This phase II trial studies how well TPIV100 and sargramostim work in treating patients with HER2 positive, stage II-III breast cancer that has residual disease after chemotherapy prior to surgery. It also studies why some HER2 positive breast cancer patients respond better to chemotherapy in combination with trastuzumab and pertuzumab. TPIV100 is a type of vaccine made from HER2 peptide that may help the body build an effective immune response to kill tumor cells that express HER2. Sargramostim... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/15/2023
Locations: Essentia Health NCI Community Oncology Research Program, Duluth, Minnesota +2 locations
Conditions: Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Register for Updates
Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies
NCT05705505
Recruiting
This study will assess the safety and efficacy of increasing doses of narazaciclib (ON 123300) in combination with the standard daily dose (2.5mg) of letrozole in patients with Recurrent Metastatic Low-grade Endometrioid Endometrial Cancer and other Gynecologic Malignancies.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota
Conditions: Endometrioid Endometrial Cancer
Register for Updates
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
NCT03129139
Recruiting
A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™Capsules given daily for 21 days followed by 7 days off schedule in patients with Advanced Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach
Register for Updates
KM3D Multicenter Cancer Consortium: Predicting Patient Response Using 3D Cell Culture Models
NCT05338073
Recruiting
This study will assess the ability of the Known Medicine platform to predict the efficacy of certain cancer drug treatments and to validate that tumor organoid drug sensitivity is representative of patient treatment outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Cancer, Predictive Cancer Model, Effects of Chemotherapy
Register for Updates
Comparison of Toxicities Between Proton Therapy and IMRT for Post Operative Treatment of Endometrial or Cervical Cancers.
NCT04745650
Recruiting
This trial is designed as a non-randomized pilot trial to study, in a preliminary fashion, whether proton radiation therapy (proton RT) reduces acute gastrointestinal toxicities at the end of treatment compared to intensity modulated radiation therapy (IMRT)
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/08/2021
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Cervical Cancer, Endometrial Cancer
Register for Updates